Revolution Medicines, Inc. (RVMDW) stock
RVMDWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMD
$9.81+0.18 (+1.82%)
Close on Oct 30, 2026Market cap $41.00BP/E –Yield –
Revolution Medicines cash
Cash and short-term investments held at the end of each period.
Revolution Medicines's cash was $3.94B at Jun 30, 2026. For fiscal 2025 it was $2.03B, down 11.5% from the year before. The highest annual figure on record is $2.29B in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.03B | -11.5% |
| FY2024 | Dec 31, 2024 | $2.29B | +23.5% |
| FY2023 | Dec 31, 2023 | $1.85B | +187.3% |
| FY2022 | Dec 31, 2022 | $644.94M | +11.8% |
| FY2021 | Dec 31, 2021 | $577.05M | +30.9% |
| FY2020 | Dec 31, 2020 | $440.74M | +259.0% |
| FY2019 | Dec 31, 2019 | $122.76M | +76.4% |
| FY2018 | Dec 31, 2018 | $69.59M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.94B | +84.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.91B | -9.3% |
| Q4 FY2025 | Dec 31, 2025 | $2.03B | -11.5% |
| Q3 FY2025 | Sep 30, 2025 | $1.93B | +24.7% |
| Q2 FY2025 | Jun 30, 2025 | $2.14B | +34.4% |
| Q1 FY2025 | Mar 31, 2025 | $2.10B | +23.4% |
| Q4 FY2024 | Dec 31, 2024 | $2.29B | +23.5% |
| Q3 FY2024 | Sep 30, 2024 | $1.55B | +90.5% |
| Q2 FY2024 | Jun 30, 2024 | $1.59B | +74.9% |
| Q1 FY2024 | Mar 31, 2024 | $1.70B | +87.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.85B | +187.3% |
| Q3 FY2023 | Sep 30, 2023 | $813.20M | +24.1% |
| Q2 FY2023 | Jun 30, 2023 | $909.49M | +97.1% |
| Q1 FY2023 | Mar 31, 2023 | $909.80M | +75.4% |
| Q4 FY2022 | Dec 31, 2022 | $644.94M | +11.8% |
| Q3 FY2022 | Sep 30, 2022 | $655.01M | +7.6% |
| Q2 FY2022 | Jun 30, 2022 | $461.43M | -28.6% |
| Q1 FY2022 | Mar 31, 2022 | $518.75M | -23.9% |
| Q4 FY2021 | Dec 31, 2021 | $577.05M | +30.9% |
| Q3 FY2021 | Sep 30, 2021 | $608.66M | +30.6% |
| Q2 FY2021 | Jun 30, 2021 | $646.32M | +98.6% |
| Q1 FY2021 | Mar 31, 2021 | $681.59M | +95.9% |
| Q4 FY2020 | Dec 31, 2020 | $440.74M | +259.0% |
| Q3 FY2020 | Sep 30, 2020 | $466.14M | +2035.9% |
| Q2 FY2020 | Jun 30, 2020 | $325.45M | +280.7% |
| Q1 FY2020 | Mar 31, 2020 | $347.95M | +454.4% |
| Q4 FY2019 | Dec 31, 2019 | $122.76M | +76.4% |
| Q3 FY2019 | Sep 30, 2019 | $21.82M | – |
| Q2 FY2019 | Jun 30, 2019 | $85.48M | – |
| Q1 FY2019 | Mar 31, 2019 | $62.76M | – |
| Q4 FY2018 | Dec 31, 2018 | $69.59M | – |